Clinical Trials Logo

Plaque Psoriasis clinical trials

View clinical trials related to Plaque Psoriasis.

Filter by:

NCT ID: NCT05357755 Completed - Plaque Psoriasis Clinical Trials

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

SUMMIT
Start date: June 13, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.

NCT ID: NCT05344482 Completed - Plaque Psoriasis Clinical Trials

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

Start date: July 9, 2020
Phase:
Study type: Observational

This study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the Dermatology Clinics of the 14 University, Training & Research Hospitals in Turkey. Data were extracted between 02 September 2020 and 29 April 2021.

NCT ID: NCT05330936 Completed - Plaque Psoriasis Clinical Trials

Comparison of Cyanocobalamin in Avocado Oil Cream With Steroid Combination Ointment

Start date: January 1, 2021
Phase: Early Phase 1
Study type: Interventional

A randomized clinical trial with two groups. Group A Group B Group A is being treated with conventional Steroid combination ointment for the treatment of chronic Plaque Psoriasis. Group B is being treated with Cyanocobalamin in Avocado Oil cream for the treatment of chronic Plaque Psoriasis. Each group having 45 patients.

NCT ID: NCT05282771 Completed - Plaque Psoriasis Clinical Trials

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

Start date: April 16, 2021
Phase: Early Phase 1
Study type: Interventional

To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045% (Reference Listed Drug) in the treatment of moderate to severe plaque psoriasis.

NCT ID: NCT05268016 Completed - Plaque Psoriasis Clinical Trials

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

Start date: March 24, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.

NCT ID: NCT05223868 Completed - Plaque Psoriasis Clinical Trials

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

FRONTIER 1
Start date: February 3, 2022
Phase: Phase 2
Study type: Interventional

Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.

NCT ID: NCT05108766 Completed - Plaque Psoriasis Clinical Trials

A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

Start date: December 17, 2020
Phase: Phase 3
Study type: Interventional

This is a phase Ⅲ, randomized, double-blind, placebo-controlled, parallel design, multicenter trial to evaluate the efficacy, safety, tolerability, and immunogenicity of subcutaneous Tildrakizumab in subjects with moderate to severe chronic plaque psoriasis. The trial was divided into two parts: the base study (Week 0- Week 12) and the extension study (Week 13- Week 54).

NCT ID: NCT05073315 Completed - Plaque Psoriasis Clinical Trials

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

Start date: October 4, 2021
Phase: Phase 3
Study type: Interventional

Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to severe plaque psoriasis. This multi-center study is composed of two periods: A lead-in period of treatment with Humira® followed by a randomized two parallel arm period.

NCT ID: NCT05046899 Completed - Plaque Psoriasis Clinical Trials

Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.

Start date: September 14, 2021
Phase: N/A
Study type: Interventional

The purpose of this investigation is to assess performance and safety of BIOpH+ Psoriasis Medical Bath in comparison to a comparative device.

NCT ID: NCT04908514 Completed - Plaque Psoriasis Clinical Trials

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Start date: May 7, 2021
Phase: Phase 2
Study type: Interventional

A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis